Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–87. https://doi.org/10.1007/s10549-016-4059-6.

Article  PubMed  Google Scholar 

Carey L, Dees E, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007:13(8). https://doi.org/10.1158/1078-0432.CCR-06-1109.

Fornier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2012;18(1):41–51. https://doi.org/10.1111/j.1524-4741.2011.01175.x.

Article  PubMed  Google Scholar 

Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;25:1275–81. https://doi.org/10.1200/JCO.2007.14.4147.

Article  Google Scholar 

Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72. https://doi.org/10.1016/S0140-6736(13)62422-8.

Article  PubMed  Google Scholar 

Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22. https://doi.org/10.1200/JCO.2007.10.6823.

Article  PubMed  Google Scholar 

Spring LM, Fell G, Arfe A, et al. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–48. https://doi.org/10.1158/1078-0432.CCR-19-3492.

Article  PubMed  PubMed Central  Google Scholar 

Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59. https://doi.org/10.1056/NEJMoa1612645.

Article  CAS  PubMed  Google Scholar 

Mayer J, Zhao F, Arteaga C, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021;39(23):2539–51. https://doi.org/10.1200/JCO.21.00976.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA 1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–405. https://doi.org/10.1056/NEJMoa2105215.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA 1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–68. https://doi.org/10.10106/j.annonc.2022.09.159.

Article  CAS  PubMed  Google Scholar 

Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485–505. https://doi.org/10.1200/JCO.20.03399.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Cores J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–67. https://doi.org/10.1056/NEJMoa2112651.

Article  CAS  PubMed  Google Scholar 

Pusztai L, Denkert C, O’Shaughnessy J, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: exploratory analysis from KEYNOTE-522. J Clin Oncol. 2022;40(16_suppl):503. https://doi.org/10.1200/JCO.2022.40.16_suppl.50.

Huober J, van Mackelenbergh M, Schneeweiss A, et al. Identifying breast cancer patients at risk of relapse despite pathologic complete response after neoadjuvant therapy. npj Breast Cancer. 2023;9(10):23. https://doi.org/10.1038/s41523-023-00525-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanioka M, Shimizu C, Yonemori K, et al. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer. 2010;103:297–302. https://doi.org/10.1038/sj.bjc.6605769.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaudry M, Lei X, Gonalez-Angulo AM, et al. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015;153:417–23. https://doi.org/10.1007/s10549-015-3533-x.

Article  CAS  PubMed  Google Scholar 

Bruzas S, Gluz O, Harbeck N, et al. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. NPJ Breast Cancer. 2022;8:42. https://doi.org/10.1038/s41523-022-00403-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network (NCCN) Guidelines® for breast cancer version 4.2023.https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed May 7, 2023.

Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9. https://doi.org/10.1038/nature10933.

Article  CAS  PubMed  Google Scholar 

Sant M, Bernat-Peguera A, Felip E, et al. Role of ctDNA in breast cancer. Cancers (Basel). 2022;14(2):310. https://doi.org/10.3390/cancers14020310.

Article  CAS  PubMed  Google Scholar 

Lin P-H, Wang M-Y, Lo C, et al. Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therap. Front Oncol. 2021;11:736769. https://doi.org/10.3389/fonc.2021.736769.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Food and Drug Administration. FDA approves elacestrant for ER-positive, HER-2 negative, ESR1-mutated advanced or metastatic breast cancer; January 27, 2023. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer#:~:text=On%20January%2027%2C%202023%2C%20the,one%20line%20of%20endocrine%20therapy. Accessed February 3, 2023.

Dawson S-J, Tsui D, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–209. https://doi.org/10.1056/NEJMoa1213261.

Article  CAS  PubMed  Google Scholar 

Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133. https://doi.org/10.1126/scitranslmed.aab0021.

Article  PubMed  Google Scholar 

Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034–47. https://doi.org/10.15252/emmm.201404913.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Hancock BA, Solzak JP, et al. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer. 2017;3:24. https://doi.org/10.1038/s41523-017-0028-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coombes RC, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255–62. https://doi.org/10.1158/1078-0432.CCR-18-3663.

Article  CAS  PubMed  Google Scholar 

Magbanua MJM, Swigart LB, Wu H-T, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann of Oncol. 2021;32(2):229–39. https://doi.org/10.1016/j.annonc.2020.11.007. This retrospective study of ctDNA to predict pCR and relapse risk showed that ctDNA clearance during NAC resulted in similar risk for relapse as those with negative ctDNA at baseline, and patients who did not clear ctDNA during NAC or post NAC remained at high risk of relapse.

Article  CAS  Google Scholar 

Bidard F-C, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018;110:560–7.

Article  PubMed  Google Scholar 

Riethdorf S, Müller V, Loibl S, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res. 2017;23:5384–93. https://doi.org/10.1158/1078-0432.CCR-17-0255.

Article  CAS  PubMed  Google Scholar 

Radovich M, Jiang G, Hancock BA, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol. 2020;6(9):1410–5. https://doi.org/10.1001/jamaoncol.2020.2295. This study demonstrated the utility of ctDNA plus CTC enumeration in predicting late relapse in TNBC patients with residual disease post NAC.

Article  PubMed  Google Scholar 

Riva F, Bidard F, Houy A, et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem. 2017;63(3):691–9. https://doi.org/10.1373/clinchem.2016.262337.

Article  CAS  PubMed  Google Scholar 

Barnell EK, Fisk B, Skidmore ZL, et al. Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer. Sci Rep. 2022;12:17732. https://doi.org/10.1038/s41598-022-20928-8. This study demonstrates the feasibility of longitudinal ctDNA monitoring at specified intervals using a customized, micro-panel.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stecklein SR, Kimler BF, Yoder R, et al. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. npj Breast Cancer 2023:9(10). Doi:https://doi.org/10.1038/s41523-023-00512-7. This study shows that ctDNA predicts RCB class in patients with residual TNBC.

Magbanua MJ, Swigart LB, Ahmed Z, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;4:1–12. https://doi.org/10.1016/j.ccell.2023.04.008. This article shows that ctDNA dynamics during NAC predicts clinical outcomes and ctDNA clearance and/or negativity despite residual disease is associated with improved survival.